Reports outline prostate cancer study findings from A.C. Siva and colleagues

According to recent research from the United States, "Through a whole-cell panning approach, we previously identified a panel of antibodies that bound to prostate cancer cell surface antigens. One such antigen, CUB domain-containing protein 1 (CDCP1), was recognized by monoclonal antibody 25A11 and is a single transmembrane molecule highly expressed in several metastatic cancers as well as on CD34(+) CD133(+) myeloid leukemic blast cells."

"We show CDCP1 expression on prostate cancer cell lines by real-time quantitative PCR (RT-qPCR), flow cytometry, and immunohistochemistry and on prostate cancer patient samples by RT-qPCR and immunohistochemical staining. In cell-based assays, antibody 25A11 inhibited prostate cancer cell migration and invasion in vitro. Further characterization showed that CDCP1 is internalized on antibody binding. When 25A11 was coupled to the cytotoxin saporin either directly or via a secondary antibody, both resulted in prostate cancer cell killing in vitro. In vivo targeting studies with an anti-CDCP1 immunotoxin showed significant inhibition of primary tumor growth as well as metastasis in a mouse xenograft model," wrote A.C. Siva and colleagues (see also Prostate Cancer).

The researchers concluded: "These data provide support for continued evaluation of anti-CDCP1 therapy for potential use in cancer in primary and metastatic disease."

Siva and colleagues published their study in Cancer Research (Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Research, 2008;68(10):3759-3766).

For additional information, contact K.S. Bowdish, Anaphore Inc., 9393 Towne Center Dr., Suite 120, San Diego, CA 92121, USA.

Publisher contact information for the journal Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Keywords: United States, San Diego, Biotechnology, Cancer Research, Cytometry, Medical Device, Metastatic Cancer, Metastatic Carcinoma, Monoclonal Antibody, Oncology, Prostate Cancer, Prostatic Neoplasms.

This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2008, Immunotherapy Weekly via NewsRx.com.

To see more of the NewsRx.com, or to subscribe, go to www.newsrx.com .

http://www.lef.org/news/LefDailyNews.htm?NewsID=7032&Section=DISEASE